Dr. Duk Kyu Kim, CEO of a Korean pharmaceutical manufacturer ZERONE CELLVANE and Chief Physician at Dr. KinVane Dermatology, was honored on October at the National Assembly Museum in Seoul, Korea. Dr. Kim received the ‘innovation Leader Award for National Health Promotion’ during the 2024 Outstanding National Assembly Members and Local Government Leaders Awards ceremony.

Dr. Kim was recognized for his contributions to public health through groundbreaking research and the world’s first patent for ‘Uniform Low-Molecular-Weight PDRN Production’ technology.

Additionally, he received a special award from Jin Sung-Joon, a member of the National Assembly’s Planning and Finance Committee, marking a rare dual recognition at the same event.

This award underscores a Korean pharmaceutical manufacturer ZERONE CELLVANE’s continuous efforts to develop innovative technologies aimed at improving public health. Leveraging its PDRN technology, the company has successfully expanded its business from pharmaceuticals to cosmetics and health supplements. Through the integration of advanced biotechnology, ZERONE CELLVANE continues to drive innovation within the medical and wellness industries.

“ZERONE CELLVANE is committed to becoming a global leader in biotechnology by advancing our PDRN technology through relentless innovation,” said Dr. Kim. “We are collaborating closely with leading researchers and medical experts both domestically and internationally to further refine this technology.

Our distribution network across North America, Europe, and Asia is steadily growing, and we will continue to dedicate ourselves to enhancing public health and improving quality of life.”

Building on this momentum, ZERONE CELLVANE has been invited to deliver a keynote presentation on its PDRN technology at the upcoming ASLS Indonesia 2024 international conference. This event will provide an opportunity for the company to showcase its proprietary technology to global experts and discuss its potential to expand biotechnology into broader international markets.

In addition, ZERONE CELLVANE’s research team has validated the regenerative and anti-inflammatory properties of PDRN, which have been incorporated into various products. The company has also made significant strides in developing treatments for intractable conditions such as diabetic wounds, further solidifying its position as a trailblazer in the biotechnology sector.

With its commitment to advancing public health through innovative technologies and its growing presence in global markets, Korean pharmaceutical manufacturer ZERONE CELLVANE is shaping a new paradigm in the medical and biotechnology industries.